Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma.
Human myeloma cells freshly isolated from 40 patients with IgG multiple myeloma (MM, 10 in stage I and 30 in stage III), were cultured for 48 hours with recombinant B cell stimulatory factor 2 (rBSF-2)/interleukin-6 (IL-6), which is considered a major growth factor for myeloma cells. Uptake of 3H-thymidine by these purified myeloma cells was measured, and BSF-2 response was evaluated by stimulation index and delta cpm induced by rBSF-2. Myeloma cells from cases in stage I responded to rBSF-2 better than those in stage III. Moreover rBSF-2 responders also showed better response to chemotherapy. Therefore, these results suggest that in vitro response of myeloma cells to BSF-2 correlates with disease progression and clinical response in patients of MM.
Asaoku
H
H
Department of Internal Medicine, Hiroshima University, Japan.
Kawano
M
M
Iwato
K
K
Tanabe
O
O
Tanaka
H
H
Hirano
T
T
Kishimoto
T
T
Kuramoto
A
A
D006801:Humans; D015850:Interleukin-6; D007378:Interleukins / Q000494:pharmacology*; D009101:Multiple Myeloma / Q000378:metabolism / Q000473:pathology*; D009367:Neoplasm Staging; D011994:Recombinant Proteins / Q000494:pharmacology; D013936:Thymidine / Q000378:metabolism; D014407:Tumor Cells, Cultured
D015850:Interleukin-6; D007378:Interleukins; D011994:Recombinant Proteins; D013936:Thymidine